{"preliminary_commentary":{"by_channel":{"x_thread":41,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03371719\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["apalutamide"]],"indication":"recurrent prostate cancer","name":"NRG-GU006","nct_id":"NCT03371719","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nrg-gu006-nct03371719. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive placebo PO QD on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm 1 (radiation therapy, placebo)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo external beam radiation therapy on day 1 for 7-8 weeks. Beginning on day of radiation therapy, patients receive apalutamide PO QD on days 1-30. Treatment repeats every 30 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.","label":"Arm 2 (radiation therapy, apalutamide)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2030-03-10","type":"ESTIMATED"},"conditions":["Recurrent Prostate Carcinoma","Stage III Prostate Adenocarcinoma AJCC v7","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":{"count":298,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Apalutamide","otherNames":["ARN 509","ARN-509","ARN509","Erleada","JNJ 56021927","JNJ-56021927"],"type":"DRUG"},{"name":"External Beam Radiation Therapy","otherNames":["Definitive Radiation Therapy","EBRT","External Beam Radiation","External Beam Radiotherapy","External Beam Radiotherapy (conventional)","External Beam RT","external radiation","External Radiation Therapy","external-beam radiation","Radiation, External Beam","Teleradiotherapy","Teletherapy","Teletherapy Radiation"],"type":"RADIATION"},{"name":"Placebo Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-10-01","lead_sponsor":"NRG Oncology","official_title":"A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-03-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Alive Without Biochemical Progression (Biochemical Progression-free Survival)","timeFrame":"From randomization to biochemical progression or last follow-up if alive. Median follow-up at time of analysis among surviving patients was 5.0 years. Five-year rates are presented."}],"references":[{"citation":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29.","pmid":"38421252","type":"DERIVED"},{"citation":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29.","pmid":"38421243","type":"DERIVED"}],"start_date":{"date":"2018-06-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial","url":"https://clinicaltrials.gov/study/NCT03371719"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nrg-gu006-nct03371719"}